Ping An Technology has announced it has completed a clinical trial of the world’s first intelligent optical coherence tomography retinal disease screening system.
Takeda has announced it is to sell the dry eye drug Xiidra to Novartis, and a surgical patch to Johnson & Johnson, for a potential total of $5.7 billion as it seeks to pay off debts fol
Novartis has filed its ophthalmology drug brolucizumab with the US regulator, a potentially strong competitor in the tough market for drugs for the degenerative eye condition wet AMD.
Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products.